Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $984547.0.

  • bioAffinity Technologies' Accumulated Expenses rose 887.97% to $984547.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $984547.0, marking a year-over-year increase of 887.97%. This contributed to the annual value of $1.4 million for FY2024, which is 2164.8% up from last year.
  • As of Q3 2025, bioAffinity Technologies' Accumulated Expenses stood at $984547.0, which was up 887.97% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Accumulated Expenses ranged from a high of $1.6 million in Q3 2022 and a low of $481336.0 during Q1 2023
  • Over the past 4 years, bioAffinity Technologies' median Accumulated Expenses value was $969093.0 (recorded in 2024), while the average stood at $960860.9.
  • The largest annual percentage gain for bioAffinity Technologies' Accumulated Expenses in the last 5 years was 11218.37% (2023), contrasted with its biggest fall of 5976.34% (2023).
  • Quarter analysis of 4 years shows bioAffinity Technologies' Accumulated Expenses stood at $541894.0 in 2022, then surged by 112.18% to $1.1 million in 2023, then grew by 21.65% to $1.4 million in 2024, then dropped by 29.61% to $984547.0 in 2025.
  • Its Accumulated Expenses stands at $984547.0 for Q3 2025, versus $1.0 million for Q2 2025 and $1.4 million for Q1 2025.